News articles about Intersect ENT (NASDAQ:XENT) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intersect ENT earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 44.1899033513857 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- ETFs with exposure to Intersect ENT, Inc. : October 10, 2017 (finance.yahoo.com)
- The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT (finance.yahoo.com)
- Buy the position in stock: Intersect ENT, Inc. (XENT) – Street Observer (press release) (streetobserver.com)
- Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 (finance.yahoo.com)
Intersect ENT (XENT) opened at 28.40 on Thursday. The company’s market cap is $828.97 million. The firm has a 50-day moving average price of $30.32 and a 200-day moving average price of $26.02. Intersect ENT has a 52-week low of $7.65 and a 52-week high of $33.25.
Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.11. The business had revenue of $24.00 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company’s quarterly revenue was up 24.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.21) EPS. On average, analysts forecast that Intersect ENT will post ($0.61) EPS for the current year.
A number of brokerages recently commented on XENT. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Thursday, October 5th. TheStreet upgraded Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Northland Securities restated a “hold” rating and issued a $25.00 price target on shares of Intersect ENT in a research report on Wednesday, August 2nd. Canaccord Genuity restated a “buy” rating and issued a $32.00 price target on shares of Intersect ENT in a research report on Wednesday, August 2nd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $35.00 price target on shares of Intersect ENT in a research report on Tuesday, August 22nd. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.70.
In other news, COO Richard E. Kaufman sold 12,500 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $28.25, for a total transaction of $353,125.00. Following the transaction, the chief operating officer now directly owns 169,821 shares in the company, valued at approximately $4,797,443.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $29.03, for a total value of $580,600.00. Following the transaction, the insider now owns 580,868 shares in the company, valued at $16,862,598.04. The disclosure for this sale can be found here. Insiders sold a total of 147,063 shares of company stock worth $4,381,229 over the last 90 days. Corporate insiders own 13.70% of the company’s stock.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.